Systematic Review and Meta-analysis of Randomised Controlled Trials Testing the Effects of Proanthocyanidins Supplementation on Lipid Profile

2021 ◽  
Author(s):  
Jingyi Ren ◽  
Yiting Sun ◽  
Jiaqi An ◽  
Fengge Chen ◽  
Bowen Yin ◽  
...  
Keyword(s):  
Systematic Review ◽  
Lipid Profile ◽  
Weighted Mean Difference ◽  
Meta Analysis ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Pooled Analysis ◽  
Lipoprotein Cholesterol ◽  
Cochrane Library ◽  
Randomised Controlled

Abstract Background: The studies that assessed proanthocyanidins (PCs) supplementation on lipid profile revealed contradictory results. The objective of this meta-analysis was to investigate the influence of PCs supplementation on lipid profile.Methods: Six databases (Pubmed, Web of Science, Cochrane Library, Scopus, EMBASE, and Google Scholar) were searched to identify for published relevant studies up to June 9, 2021. The weighted mean difference (WMD) and the corresponding standard deviations (SD) of the total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), and triglycerides (TG) were calculated to estimate the pooled effect. Results: A total of 1411 articles were identified through database searching, of which, seven studies were included in the meta-analysis. Pooled analysis suggested that PCs supplementation effectively affected the level of HDL-C (WMD: 2.716, 95% CI: 0.269, 5.163, p = 0.030), but had no significant effect on TC (WMD: -0.201, 95% CI: -6.443, 6.041, p=0.950), LDL-C (WMD: -3.000, 95% CI: -8.254, 2.254, p = 0.263), and TG (WMD: -8.874, 95% CI: -21.009, 3.260, p =0.152). In the subgroup analyses, a significant enhance in HDL-C in people with a shorter intervention duration (duration < 12 weeks) or people with a higher BMI (BMI ≥ 24 kg/m2). Conclusion: The present systematic review and meta-analysis suggest that PCs supplementation had no effects on TC, LDL-C or TG, whereas it may contribute to a change on HDL-C. Additional high-quality studies are needed to confirm this result.

scholarly journals Sulforaphane ameliorates lipid profile in rodents: an updated systematic review and meta-analysis

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Kaili Du ◽  
Yuxin Fan ◽  
Dan Li
Keyword(s):  
Systematic Review ◽  
Weight Control ◽  
Weighted Mean Difference ◽  
Meta Analysis ◽  
Low Density Lipoprotein ◽  
Disease Model ◽  
Density Lipoprotein ◽  
Liver Weight ◽  
Lipoprotein Cholesterol ◽  
Alcoholic Fatty Liver

AbstractSulforaphane (SFN), a naturally-occurring isothiocyanate enriched in cabbage and broccoli, has been provided as food supplements to improve weight management and reduce lipid levels. However, its effects on serum lipid profiles are contradictory. In this review, a meta-analysis and systematic review of SFN on lipid reduction and weight control is assessed with mice and rats fed on high-fat diet. The effects of SFN supplementation were evaluated by weighted mean difference (WMD) in body weight (BW), liver weight (LW) and also by its effect on serum lipids. A random-effects model was applied to estimate the overall summary effect. SFN reduced BW (WMD: − 2.76 g, 95% CI: − 4.19, − 1.34) and LW (WMD: − 0.93 g, 95% CI: − 1.63, − 0.23) significantly in our ten trials. Its effects on serum total cholesterol (TC) (WMD: − 15.62 mg/dL, 95% CI: − 24.07, − 7.18), low-density lipoprotein cholesterol (LDL-C) (WMD: − 8.35 mg/dL, 95% CI: − 15.47, − 1.24) and triglyceride (TG) (WMD: − 40.85 mg/dL, 95% CI: − 67.46, − 14.24) were significant except for high-density lipoprotein cholesterol (HDL-C) component (WMD: 1.05 mg/dL, 95% CI: − 3.44, 5.54). However, species, disease model, duration, SFN dosage as well as route of administration did not explain the heterogeneity among studies. In summary, these findings provide new insights concerning preclinical strategies for treating diseases including obesity, diabetes, hypertension, non-alcoholic fatty liver disease as well as cardiovascular disease with SFN supplements.

scholarly journals Potential Biomarkers for Post-Stroke Cognitive Impairment: A Systematic Review and Meta-Analysis

2022 ◽  
Vol 23 (2) ◽  
pp. 602
Author(s):  
Ka Young Kim ◽  
Ki Young Shin ◽  
Keun-A Chang
Keyword(s):  
Systematic Review ◽  
Uric Acid ◽  
Cognitive Impairment ◽  
Meta Analysis ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Lipoprotein Cholesterol ◽  
Cochrane Library ◽  
Blood Proteins ◽  
Post Stroke

Stroke is a primary debilitating disease in adults, occurring in 15 million individuals each year and causing high mortality and disability rates. The latest estimate revealed that stroke is currently the second leading cause of death worldwide. Post-stroke cognitive impairment (PSCI), one of the major complications after stroke, is frequently underdiagnosed. However, stroke has been reported to increase the risk of cognitive impairment by at least five to eight times. In recent decades, peripheral blood molecular biomarkers for stroke have emerged as diagnostic, prognostic, and therapeutic targets. In this study, we aimed to evaluate some blood-derived proteins for stroke, especially related to brain damage and cognitive impairments, by conducting a systematic review and meta-analysis and discussing the possibility of these proteins as biomarkers for PSCI. Articles published before 26 July 2021 were searched in PubMed, Embase, the Web of Science, and the Cochrane Library to identify all relevant studies reporting blood biomarkers in patients with stroke. Among 1820 articles, 40 were finally identified for this study. We meta-analyzed eight peripheral biomarker candidates: homocysteine (Hcy), high-density lipoprotein cholesterol (HDL-C), C-reactive protein (CRP), low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), triglyceride (TG), uric acid, and glycated hemoglobin (HbA1c). The Hcy, CRP, TC, and LDL-C levels were significantly higher in patients with PSCI than in the non-PSCI group; however, the HDL-C, TG, uric acid, and HbA1c levels were not different between the two groups. Based on our findings, we suggest the Hcy, CRP, TC, and LDL-C as possible biomarkers in patients with post-stroke cognitive impairment. Thus, certain blood proteins could be suggested as effective biomarkers for PSCI.

scholarly journals The effect of l-arginine supplementation on lipid profile: a systematic review and meta-analysis of randomised controlled trials

2019 ◽  
Vol 122 (9) ◽  
pp. 1021-1032
Author(s):  
Amir Hadi ◽  
Arman Arab ◽  
Sajjad Moradi ◽  
Ana Pantovic ◽  
Cain C. T. Clark ◽  
...  
Keyword(s):  
Systematic Review ◽  
Lipid Profile ◽  
Randomised Controlled Trials ◽  
Weighted Mean Difference ◽  
Meta Analysis ◽  
Cochrane Library ◽  
Controlled Trials ◽  
Inconsistency Index ◽  
Randomised Controlled ◽  
Arginine Supplementation

AbstractA number of clinical trials have examined the effect of l-arginine on lipid profile in recent years; however, the results remain equivocal. Therefore, the present study aims to summarise and quantitatively examine the available evidence on the effectiveness l-arginine supplementation on lipid parameters using a systematic review and meta-analytic approach. Online databases including PubMed, Scopus, ISI Web of Science, Cochrane Library and Google Scholar were searched up to April 2019 for randomised controlled trials that examined the effect of l-arginine supplementation on lipid profile in adults. Treatment effects were expressed as weighted mean difference (WMD) and the corresponding standard error in concentrations of serum lipids. To estimate the overall effect of l-arginine supplementation, we used the random-effects model. In total, twelve studies were included in the systematic review. The meta-analysis revealed that l-arginine supplementation did not significantly change the concentrations of total cholesterol (WMD: –5·03 mg/dl; 95 % CI –10·78, 0·73; P = 0·08; inconsistency index (I2) = 39·0 %), LDL (WMD: –0·47 mg/dl; 95 % CI –3·61, 2·66; P = 0·76; I2 = 0·0 %), or HDL (WMD: 0·57 mg/dl; 95 % CI –1·28, 2·43; P = 0·54; I2 = 68·4 %). A significant reduction was observed only in serum TAG levels (WMD: –7·04 mg/dl; 95 % CI –11·42, –2·67; P < 0·001; I2 = 0·0 %). This meta-analysis concludes that l-arginine supplementation can significantly reduce blood TAG levels; however, there is insufficient evidence to support its hypocholesterolaemic effects. To draw straightforward conclusions regarding generalised recommendations for l-arginine supplementation for improving lipid profile, there is a need for more well-controlled trials targeting exclusively patients with dyslipidaemia.

scholarly journals Association Between Cardiac Natriuretic Peptides and Lipid Profile: a Systematic Review and Meta-Analysis

2019 ◽  
Vol 9 (1) ◽  
Author(s):  
Francesco Spannella ◽  
Federico Giulietti ◽  
Marica Bordicchia ◽  
John C. Burnett ◽  
Riccardo Sarzani
Keyword(s):  
Systematic Review ◽  
Lipid Profile ◽  
Natriuretic Peptides ◽  
Meta Analysis ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Lipoprotein Cholesterol ◽  
Glucose And Lipid Metabolism ◽  
Cardiac Natriuretic Peptides ◽  
Metabolic Properties

AbstractCardiac natriuretic peptides (NPs) play a fundamental role in maintaining cardiovascular (CV) and renal homeostasis. Moreover, they also affect glucose and lipid metabolism. We performed a systematic review and meta-analysis of studies investigating the association of NPs with serum lipid profile. A PubMed and Scopus search (2005–2018) revealed 48 studies reporting the association between NPs and components of lipid profile [total cholesterol (TC), low-density lipoprotein cholesterol (LDLc), high-density lipoprotein cholesterol (HDLc) and triglycerides (TG)]. Despite high inconsistency across studies, NPs levels were inversely associated with TC [k = 32; pooled r = −0.09; I2 = 90.26%], LDLc [k = 31; pooled r = −0.09; I2 = 82.38%] and TG [k = 46; pooled r = −0.11; I2 = 94.14%], while they were directly associated with HDLc [k = 41; pooled r = 0.06; I2 = 87.94%]. The relationship with LDLc, HDLc and TG lost significance if only studies on special populations (works including subjects with relevant acute or chronic conditions that could have significantly affected the circulating levels of NPs or lipid profile) or low-quality studies were taken into account. The present study highlights an association between higher NP levels and a favorable lipid profile. This confirms and extends our understanding of the metabolic properties of cardiac NPs and their potential in CV prevention.

scholarly journals Sulforaphane ameliorates lipid profile in rodents: An updated systematic review and meta-analysis

2020 ◽  
Author(s):  
Dan Li ◽  
Kaili Du ◽  
Yuxin Fan
Keyword(s):  
Systematic Review ◽  
Body Weight ◽  
Lipid Profile ◽  
Weight Control ◽  
Weighted Mean Difference ◽  
Meta Analysis ◽  
Density Lipoprotein ◽  
Liver Weight ◽  
Lipoprotein Cholesterol ◽  
Alcoholic Fatty Liver

Abstract Sulforaphane (SFN) which is enriched in cabbage and broccoli, a naturally-occurring isothiocyanate, has been provided as food supplements to improve weight management and reduce lipid levels. However, its effects on serum lipid profile are contradictory. In this review, a meta-analysis and systematic review of SFN on lipids reduction and weight control is assessed with mice and rats fed with high-fat diet. The effects of SFN supplementation were evaluated by weighted mean difference (WMD) and the corresponding standard error of body weight, liver weight and concentrations of lipids. A random-effects model was chosen to estimate the overall summary effect. Our analytic results of the meta-analysis revealed that SFN can reduce body weight (WMD: -2.76 g, 95% CI: -4.19, -1.34) and liver weight (WMD: -0.93 g, 95% CI: -1.63, -0.23) significantly from ten trials. Its effects on serum total cholesterol (WMD: -15.62 mg/dL, 95% CI: -24.07, -7.18), low-density lipoprotein cholesterol (WMD: -8.35 mg/dL, 95% CI: -15.47, -1.24) and triglyceride (WMD: -40.85 mg/dL, 95% CI: -67.46, -14.24) were significant except for high-density lipoprotein cholesterol (WMD: 1.05 mg/dL, 95% CI: -3.44, 5.54). The subgroup analytic results from findings unveiled that classifying studies according to species, disease model, duration, SFN dosage as well as administration route could not explain the heterogeneity among studies and change the results. In summary, these findings provide new insights concerning preclinical strategies for treating diseases including obesity, diabetes, hypertension, non-alcoholic fatty liver disease as well as cardiovascular disease with SFN supplements.

scholarly journals The efficacy of evolocumab in the management of hyperlipidemia: a systematic review

2017 ◽  
Vol 11 (5-6) ◽  
pp. 155-169 ◽  
Author(s):  
Lamia AlHajri ◽  
Asma AlHadhrami ◽  
Shama AlMheiri ◽  
Yalwah AlMutawa ◽  
Zainab AlHashimi
Keyword(s):  
Systematic Review ◽  
Side Effects ◽  
Lipid Profile ◽  
Data Extraction ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Lipoprotein Cholesterol ◽  
Pcsk9 Inhibitors ◽  
Lipid Management ◽  
Highly Effective

Background: Hyperlipidemia or dyslipidemia has been a concern for a long time, with various guidelines emphasizing the importance of managing the lipid profile to prevent cardiac incidences. Although statins have been found to be highly effective, resistance and intolerability to side effects will continue to be a stumbling block for certain patients. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors tackle lipid profile via a novel mechanism and therefore provide an additional effective option for managing lipid profile. The overarching aim of this systematic review was to evaluate the efficacy of evolocumab among various populations with hypercholesterolemia. Methods: A comprehensive search was conducted in ProQuest Health & Medical Complete, Google Scholar, ScienceDirect, and PubMed to identify potential records; then titles, abstracts, and full texts were screened using the inclusion criteria to filter out irrelevant studies. Data extraction and quality assessment were undertaken using standardized tools and the results were narratively synthesized and presented in tables. Results: Eight studies were included in this systematic review after screening 1191 records. All studies demonstrated a statistically significant reduction in low-density lipoprotein cholesterol (LDL-C) values in the groups that received evolocumab compared with the comparator groups ( p < 0.05). The decline in LDL-C levels from baseline in the majority of studies ranged from 40% to 80%, whether used alone or in combination with other agents. Also, high-density lipoprotein cholesterol, lipoprotein (a) and apolipoprotein B were improved with the use of evolocumab. Conclusions: This study helped to collate evidence from studies that tested the effectiveness of evolocumab in the management of hyperlipidemia. Evolocumab seems to be highly effective in reducing LDL-C and other lipid parameters. Hence, it provides an excellent alternative for patients with refractory disease or patients who develop intolerable side effects, therefore helping to overcome the stumbling block to achieving optimal lipid management.

Sign in / Sign up

Export Citation Format

Share Document